Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Daltonics, CombiMatrix, Acacia, Sigma-Aldrich

Premium
Bruker Daltonics Revs up 2 Percent in Q2, Life Science Systems Down
 
Bruker BioSciences’ Daltonics division’s revenues climbed 2 percent to $40.6 million during its second quarter, compared to $39.8 million a year ago, according to a document filed with the US Securities and Exchange Commission last week.
 
Bruker Daltonics houses Bruker’s proteomics instruments. Bruker BioSciences released its earnings for the three months ended June 30 in late July, saying company-wide revenues grew 21.1 percent, but did not elaborate on the performance of its separate divisions [See PM 08/02/07].
 
In its SEC filing, the company said Daltonics’ sales were affected by “reduced OEM sales for certain life science systems, decreased direct life science system sales, and lower grant revenue.” These were offset partially by “increased sales of [chemical, biological, radiological and nuclear] detection systems and aftermarket revenue,” including accessory sales, consumables, training and services.
 
Sales in life science systems slid 7.4 percent to $28.4 million during the quarter from $30.7 million a year ago.
 

 
CombiMatrix Completes Divorce from Acacia
 
CombiMatrix this week completed its split from Acacia Research and began trading on the Nasdaq Capital Market under ticker symbol CBMXD. After an introductory period, the company’s trading symbol will be CBMX.
 
CombiMatrix had filed with the US Securities and Exchange Commission at the end of last year to split from Acacia, saying that Acacia’s business was different from its own and Acacia’s business exposed Combimatrix to patent litigation that otherwise would not be part of its business.
 
As a result of the split, every 10 shares of Acacia-Research-CombiMatrix common stock is being redeemed for one share of CombiMatrix common stock.
 

 
Sigma-Aldrich Declares Quarterly Dividend
 
Sigma-Aldrich’s board this week approved a quarterly dividend of $.115 per share. It is payable on Sept. 14 to shareholders of record as of Aug. 31.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.